AIM ImmunoTech Inc.
$0.21
-$0.00 (-0.75%)
$0.21Day Range$0.22
Key Statistics
Market Cap
$8.37M
Shares Outstanding
39.2M
Primary Exchange
XASE
Currency
USD
Type
CS
IPO Date
Nov 2, 1995
Round Lot
100
Locale
US
Trading Data
Day Open
$0.21
Day High
$0.22
Day Low
$0.21
Volume
2.46M
VWAP
$0.21
Prev Close
$0.21
Transactions
--
Acc. Volume
--
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283621 employees2117 SW HIGHWAY 484, OCALA, FL, 32801352-448-7797IPO Nov 2, 1995US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000946644
- Composite FIGI
- BBG000JL6Z80
- Share Class FIGI
- BBG001SB9J29
- Ticker Root
- AIM
- SIC Code
- 2836
About AIM ImmunoTech Inc. (AIM) Stock
AIM ImmunoTech Inc. (AIM) closed the 2026-09-16 session at $0.21, down 0.75% versus the previous close (-0.00). The stock opened at $0.21 and traded between $0.21 and $0.22 during that session. Session trading volume was 2.5M shares. The volume-weighted average price (VWAP) is $0.21.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
AIM ImmunoTech Inc. has a market capitalization of $8.4 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. AIM is listed on the XASE exchange. The company employs approximately 21 people. AIM ImmunoTech Inc. is headquartered in OCALA, FL. The recorded listing date is 1995-11-02.
On this page you can find market AIM stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.